Trial Profile
A randomized double blind, placebo-controlled clinical trial to assess the effects of taspoglutide (RO5073031) on cardiovascular outcomes in subjects with inadequately controlled type 2 diabetes and established cardiovascular disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Taspoglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms EMERGE-8; T-EMERGE-8
- Sponsors Roche
- 27 Jul 2012 Additional lead trial centre, investigators identified as reported by Clinical Trials Registry - India.
- 12 Jul 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 12 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.